Duality Biotherapeutics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries, has enrolled over 2000 patients for multiple clinical-stage ADC candidates.
Additionally, DualityBio have established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing "Super ADCs," including bispecific ADCs, novel-payload ADCs, and autoimmune ADCs. For more information, please visit www.dualitybiologics.com.
Leveraging our experienced R&D team, profound insights into ADC design, and robust execution capabilities, Duality Biologics has established four cutting-edge ADC technology platforms: DITAC, DIBAC, DIMAC, and DUPAC. These platforms not only push the boundaries of ADC treatment but also serve as the foundation for continuous innovation and value creation. Our technology platforms have been validated by our pipeline assets and recognized by global multinational corporation (“MNC”) partners.
Leveraging our multifunctional drug development platform, we are engaged in the development of novel ADCs (Antibody-Drug Conjugates) to fully unleash the potential of ADCs in unexplored therapeutic areas. Duality has established a robust pipeline comprising 12 self-developed ADC candidates, including 7 ADCs in clinical stages, 2 next-generation bispecific ADCs, and 1 ADC for autoimmune diseases, with several other ADCs in preclinical stages.
Scan the code to follow DualityBio official wechat
Phone：021-2601 8730
Address：Full floor, 11th floor, tower a, Datang International Plaza,China
Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai
